News
NETRF Researchers Named as World’s Most Influential Scientists for 2018
Clarivate Analytics has released the most influential researcher list for 2018, which identifies exceptional researchers whose highly cited work is among the top 1% in their field around the world.
Ga-68 Dotatate PET/CT Scan for Neuroendocrine Tumors
If you’ve ever been tested for eyeglasses, you know how one lens can create grainy, foggy images and the next crisp, clear letters. That’s the kind of difference you can see between the Gallium-68 PET/CT scan and prior technology. But are these newer imaging techniques better? And who stands to benefit most from them?
Inherited Risk Factors for NETs
Many patients and families facing a neuroendocrine tumor (NET) diagnosis wonder if they inherited the disease from their parents or if they can pass it
DC Walk for Carcinoid Cancer Exceeds Fundraising Goals
Despite a gusty, northerly breeze and temperatures in the high 30s, 177 walkers, 18 volunteers, and many family dogs turned out for the first-ever DC
Pancreatic Neuroendocrine Cancer vs. Pancreatic Cancer
What is the difference between a pancreatic neuroendocrine tumor and a pancreatic tumor? A few high profile celebrities, Aretha Franklin and Steve Jobs, have died
Tb-161: Novel Radionuclide to be Tested
Early Research on Targeting Single Cancer Cells to Prevent Metastasis Despite the effectiveness of Peptide Receptor Radionuclide Therapy (PRRT) to prolong survival of those with
CarGurus Makes Grant to NETRF
The Neuroendocrine Tumor Research Foundation (NETRF) gratefully received a $35,000 donation for NET research from the CarGurus Charitable Giving Fund. NETRF was nominated by a
New Grant Explores Novel Drug Delivery System
Antibody-drug conjugate aims to combine the benefits of targeted therapy and chemotherapy Renata Jaskula-Sztul, PhD, Assistant Professor of Surgical Oncology at the University of Alabama
Navigating Neuroendocrine Tumors: New NCCN Guidelines for Patients
The National Comprehensive Cancer Network® (NCCN®) has published a brand new NCCN Guidelines for Patients focused on neuroendocrine tumor (NET). These new guidelines offer up-to-date
Brendan P. Foley Jr. Joins NETRF Board of Directors
We are proud to welcome Brendan P. Foley, Jr. as the newest member of the NET Research Foundation Board of Directors. Brendan has been elected